For the Inventor, By the Inventor

Enter assignee name

Genfit

USPTO Granted Patents = 67

CIPO Patents = 43

EPO Patents = 29

Trademarks = 28

Forward Citations = 240

Loading Chart...

Loading Chart...

54 inventors (with patents filed for the assignee):

Robert Walczak (24 out of 24 patents)

Rémy Hanf (23 out of 23 patents)

Raphael Darteil (14 out of 14 patents)

4. Karine Caumont-Bertrand (13 out of 13 patents)

5. Carole Belanger (12 out of 12 patents)

6. Dean Hum (10 out of 10 patents)

7. Jean-Francois Delhomel (9 out of 9 patents)

8. Philippe Delataille (8 out of 8 patents)

9. Ingrid Dufour (8 out of 8 patents)

10. Peggy Parroche (7 out of 7 patents)

11. Enrico Perspicace (6 out of 6 patents)

12. Zouher Majd (6 out of 6 patents)

13. Emilie Negro (6 out of 6 patents)

14. Pierre Daubersies (6 out of 6 patents)

15. Jamila Najib (6 out of 6 patents)

Core Competencies:

Combination Therapy

GLP-1 Receptor Agonists

RORgamma Modulators

Cholestatic Diseases

Non-Alcoholic Steatohepatitis

Elafibranor

Anti-Fibrotic Agents

Histological Image Analysis

Pharmaceutical Compositions

Liver Disorders

Rev-Erb Agonists

Fibrotic Diseases

67 patents: Sort by Forward Citations

1. 12458612 - Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists (2025-11-04),

2. 12391712 - Phosphate derivatives of RORgamma modulators and uses thereof (2025-08-19),

3. 12310935 - Methods of treatment of cholestatic diseases (2025-05-27),

4. 12303480 - Methods of treatment of cholestatic diseases (2025-05-20),

5. 12295928 - Methods of treatment of cholestatic diseases (2025-05-13),

6. 12295927 - Methods of treatment of cholestatic diseases (2025-05-13),

7. 12290498 - Methods of treatment of cholestatic diseases (2025-05-06),

8. 12233038 - Methods of treatment of cholestatic diseases (2025-02-25),

9. 12208087 - Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation (2025-01-28),

10. 12104209 - Non-invasive diagnostic of non-alcoholic steatohepatitis (2024-10-01),

11. 12053456 - Pharmaceutical compositions for combination therapy (2024-08-06),

12. 12053445 - Methods of treatment of cholestatic diseases (2024-08-06),

13. 12030840 - Elafibranor salts (2024-07-09),

14. 11974997 - RORgamma modulators and uses thereof (2024-05-07),

15. 11857523 - Methods of treatment of cholestatic diseases (2024-01-02),

Genfit is a biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases. With a strong expertise in the field of liver diseases, Genfit is dedicated to improving the health of millions of patients worldwide through advanced research and development efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

67 Patents

#1 in Loos

#360 in France

#10,593 in the World

Genfit

Forward Citations = 240

54 inventors:

Robert Walczak (24 out of 24 patents)

Rémy Hanf (23 out of 23 patents)

Raphael Darteil (14 out of 14 patents)

4. Karine Caumont-Bertrand (13 out of 13 patents)

5. Carole Belanger (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…